Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation

Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the pre...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical investigation Vol. 45; no. 10; pp. 1060 - 1068
Main Authors Gervasini, Guillermo, García-Cerrada, Montserrat, Vergara, Esther, García-Pino, Guadalupe, Alvarado, Raul, Fernández-Cavada, Maria Jesús, Barroso, Sergio, Doblaré, Emilio, Cubero, Juan José
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.10.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation. Design One‐hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP‐mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting. Results The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45–13·37), P < 0·01] and lower death‐censored graft survival [107·90 (84·19–131·62) vs. 176·89 (166·47–187·32) months for CYP2J2*1/*1 grafts; log‐rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively). Conclusions Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation.
AbstractList Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation. One-hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP-mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting. The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45-13·37), P < 0·01] and lower death-censored graft survival [107·90 (84·19-131·62) vs. 176·89 (166·47-187·32) months for CYP2J2*1/*1 grafts; log-rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively). Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation.
BACKGROUNDArachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation.DESIGNOne-hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP-mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting.RESULTSThe CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45-13·37), P < 0·01] and lower death-censored graft survival [107·90 (84·19-131·62) vs. 176·89 (166·47-187·32) months for CYP2J2*1/*1 grafts; log-rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively).CONCLUSIONSTaken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation.
Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation. Design One‐hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP‐mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting. Results The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45–13·37), P < 0·01] and lower death‐censored graft survival [107·90 (84·19–131·62) vs. 176·89 (166·47–187·32) months for CYP2J2*1/*1 grafts; log‐rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively). Conclusions Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation.
Author Alvarado, Raul
García-Cerrada, Montserrat
Doblaré, Emilio
Gervasini, Guillermo
Vergara, Esther
Fernández-Cavada, Maria Jesús
Barroso, Sergio
Cubero, Juan José
García-Pino, Guadalupe
Author_xml – sequence: 1
  givenname: Guillermo
  surname: Gervasini
  fullname: Gervasini, Guillermo
  email: ggervasi@unex.es
  organization: Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
– sequence: 2
  givenname: Montserrat
  surname: García-Cerrada
  fullname: García-Cerrada, Montserrat
  organization: Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
– sequence: 3
  givenname: Esther
  surname: Vergara
  fullname: Vergara, Esther
  organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 4
  givenname: Guadalupe
  surname: García-Pino
  fullname: García-Pino, Guadalupe
  organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 5
  givenname: Raul
  surname: Alvarado
  fullname: Alvarado, Raul
  organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 6
  givenname: Maria Jesús
  surname: Fernández-Cavada
  fullname: Fernández-Cavada, Maria Jesús
  organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 7
  givenname: Sergio
  surname: Barroso
  fullname: Barroso, Sergio
  organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 8
  givenname: Emilio
  surname: Doblaré
  fullname: Doblaré, Emilio
  organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain
– sequence: 9
  givenname: Juan José
  surname: Cubero
  fullname: Cubero, Juan José
  organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26214067$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1vEzEQhi3UiqaFA38A-QiHbf2x648jhBJatVAkEOJkOfasYthdp7Yjmn9f07Q9VALL0kij5x3NPIdob4oTIPSKkmNa3wm4cExZR-QzNKNcdA3jgu2hGSG0bZiW7AAd5vyLEKIoZ8_RAROMtkTIGbJXcdiOMa1XIY8ZhwnPf141I_hgC3hsk3Wr4OMUHLYueJzipkDGtu_BFVxWgGvDxbHWHieY7IBLslNeD3YqtoQ4vUD7vR0yvLyvR-j7x9Nv80_NxZfF2fzdReNazmXjnGZaO9X2tPMgFNVeQ299S1z9Soul1EJQrrRnjkjpW6U7zhWwZasdB36E3uzmrlO83kAuZgzZwVAXgbjJhkoqWEcVUxV9fY9ulvVUs05htGlrHrRU4O0OcCnmnKB_RCgxf5WbqtzcKa_syRPWhd3lVUQY_pf4EwbY_nu0OZ2fPSSaXSLkAjePCZt-m7qt7MyPzwvzdcEuz_X7S_OB3wIbyaC_
CitedBy_id crossref_primary_10_1002_jev2_12026
crossref_primary_10_1002_phar_1928
crossref_primary_10_1016_j_kint_2022_04_033
crossref_primary_10_3390_ijms222112029
crossref_primary_10_1038_s41598_021_83274_1
crossref_primary_10_1080_03007995_2017_1391757
crossref_primary_10_1681_ASN_2017030252
crossref_primary_10_1111_eci_12819
crossref_primary_10_1038_s41397_019_0128_7
crossref_primary_10_3390_jcm10173980
crossref_primary_10_1080_07853890_2019_1614656
crossref_primary_10_1371_journal_pone_0224129
crossref_primary_10_1016_j_mce_2015_10_009
Cites_doi 10.1097/00008571-199402000-00005
10.1016/j.prostaglandins.2009.04.004
10.1161/01.HYP.0000182658.04299.15
10.1126/science.285.5431.1276
10.1161/01.RES.0000139436.89654.c8
10.1097/00007691-200412000-00004
10.1016/j.prostaglandins.2011.11.007
10.1073/pnas.91.15.7002
10.1016/j.bbrc.2004.12.116
10.1097/00008571-200110000-00006
10.1016/j.atherosclerosis.2006.11.001
10.1006/abbi.1996.0229
10.1177/1076029611436197
10.1161/01.STR.0000016332.37292.59
10.1016/S0006-2952(02)01354-0
10.1111/j.1432-2277.2008.00829.x
10.1007/s00228-012-1355-x
10.1006/abbi.1995.1438
10.1074/jbc.272.19.12551
10.1016/S0003-4975(03)00735-5
10.1097/01.hjh.0000244944.34546.8e
10.1097/FPC.0000000000000045
10.1124/jpet.110.167510
10.1152/physiolgenomics.00003.2007
10.1096/fj.10-171488
10.1124/jpet.109.159863
10.1152/ajprenal.00350.2004
10.1097/00008571-199608000-00007
10.1161/01.CIR.0000143832.91812.60
10.1096/fj.10-160119
10.1161/01.CIR.0000151309.82473.59
10.1124/mol.61.4.840
10.1111/j.1432-2277.2012.01446.x
10.1074/jbc.275.6.4118
10.1016/j.atherosclerosis.2009.06.009
10.1002/jcph.15
10.1097/FPC.0b013e32830e1e16
10.1016/j.transproceed.2008.03.137
10.1540/jsmr.41.175
10.1074/jbc.R100030200
ContentType Journal Article
Copyright 2015 Stichting European Society for Clinical Investigation Journal Foundation
2015 Stichting European Society for Clinical Investigation Journal Foundation.
Copyright_xml – notice: 2015 Stichting European Society for Clinical Investigation Journal Foundation
– notice: 2015 Stichting European Society for Clinical Investigation Journal Foundation.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/eci.12507
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2362
EndPage 1068
ExternalDocumentID 26214067
10_1111_eci_12507
ECI12507
ark_67375_WNG_QG2MJ9BM_D
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Comercio e Innovacion
– fundername: Association for the Study and Prevention of Renal Diseases (ASEPER)
– fundername: Junta de Extremadura
  funderid: GR10022
– fundername: Consejeria de Economia
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c4337-cc9299c84f15de6819d9efad40c40c896b79661389d2c077d4895338e2b49c3e3
IEDL.DBID DR2
ISSN 0014-2972
IngestDate Thu Jul 10 19:55:10 EDT 2025
Wed Feb 19 01:57:46 EST 2025
Thu Apr 24 22:57:21 EDT 2025
Tue Jul 01 00:53:25 EDT 2025
Wed Jan 22 16:43:04 EST 2025
Wed Oct 30 09:52:21 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords graft survival
Creatinine clearance
CYP450
polymorphisms
delayed graft function
renal transplant
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2015 Stichting European Society for Clinical Investigation Journal Foundation.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4337-cc9299c84f15de6819d9efad40c40c896b79661389d2c077d4895338e2b49c3e3
Notes Comercio e Innovacion
Figure S1. Epoxygenase and hydroxylase pathways of arachidonic acid metabolismTable S1. Multivariate logistic regression model for the risk of delayed graft function in renal transplant recipients. Table S2. Creatinine clearance values at the four time-points considered stratified by donor and recipient genotype. Table S3. Serum creatinine concentrations (mg/dL) stratified by donor and recipient genotype at the four time-points considered.
Junta de Extremadura - No. GR10022
ArticleID:ECI12507
istex:804031AFD3A13F26552581D3E8AD73DA4DE0766F
Association for the Study and Prevention of Renal Diseases (ASEPER)
Consejeria de Economia
ark:/67375/WNG-QG2MJ9BM-D
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26214067
PQID 1716251828
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1716251828
pubmed_primary_26214067
crossref_primary_10_1111_eci_12507
crossref_citationtrail_10_1111_eci_12507
wiley_primary_10_1111_eci_12507_ECI12507
istex_primary_ark_67375_WNG_QG2MJ9BM_D
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2015
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: October 2015
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle European journal of clinical investigation
PublicationTitleAlternate Eur J Clin Invest
PublicationYear 2015
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330:87-96.
King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52.
Fu Z, Ma Y, Xie X, Huang D, Yang H, Nakayama T et al. A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 2013;19:60-5.
Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256-62.
Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14.
Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6.
Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7.
Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002;33:1677-84.
Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276:36059-62.
Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6.
Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994;91:7002-6.
Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013;69:385-93.
Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74-81.
Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24:3770-81.
Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005;41:175-93.
Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34.
Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111:63-9.
Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat 2009;89:43-51.
Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012;25:471-80.
Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg 2003;76:1623-30.
Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9.
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D et al. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010;332:57-65.
Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600-8.
Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89.
Dolegowska B, Blogowski W, Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report Transpl Int 2009;22:546-53.
Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011;25:703-13.
Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46:766-71.
Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275:4118-26.
Hermann M, Hellermann JP, Quitzau K, Hoffmann MM, Gasser T, Meinertz T et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207:476-9.
Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-94.
Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995;322:76-86.
Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503.
Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012;98:75-85.
Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24:1965-70.
Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206.
Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18:943-53.
2009; 89
2009; 22
2013; 69
2005; 111
1997; 272
2008; 18
2004; 26
2002; 33
1999; 285
2005; 41
2014; 24
2000; 275
2007; 30
2012; 98
2003; 76
2005; 46
2001; 276
2013; 19
2004; 110
2004; 95
2010; 24
2002; 64
2007; 195
2006; 24
2002; 61
2005; 289
2010; 334
2013; 53
2010; 332
2005; 327
1996; 330
1995; 322
2011; 25
2001; 11
2012; 25
1994; 91
2009; 207
2008; 40
1994; 4
1996; 6
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_40_1
Woillard JB (e_1_2_9_41_1) 2014; 24
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – reference: Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
– reference: Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat 2009;89:43-51.
– reference: Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012;98:75-85.
– reference: Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D et al. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010;332:57-65.
– reference: Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206.
– reference: Dolegowska B, Blogowski W, Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report Transpl Int 2009;22:546-53.
– reference: Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012;25:471-80.
– reference: Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89.
– reference: Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002;33:1677-84.
– reference: Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-94.
– reference: Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
– reference: Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14.
– reference: Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995;322:76-86.
– reference: Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256-62.
– reference: King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52.
– reference: Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34.
– reference: Fu Z, Ma Y, Xie X, Huang D, Yang H, Nakayama T et al. A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 2013;19:60-5.
– reference: Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9.
– reference: Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005;41:175-93.
– reference: Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275:4118-26.
– reference: Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18:943-53.
– reference: Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330:87-96.
– reference: Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
– reference: Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111:63-9.
– reference: Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74-81.
– reference: Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg 2003;76:1623-30.
– reference: Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
– reference: Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994;91:7002-6.
– reference: Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7.
– reference: Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46:766-71.
– reference: Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276:36059-62.
– reference: Hermann M, Hellermann JP, Quitzau K, Hoffmann MM, Gasser T, Meinertz T et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207:476-9.
– reference: Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013;69:385-93.
– reference: Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24:3770-81.
– reference: Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600-8.
– reference: Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503.
– reference: Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011;25:703-13.
– reference: Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24:1965-70.
– reference: Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6.
– reference: Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6.
– volume: 24
  start-page: 3770
  year: 2010
  end-page: 81
  article-title: Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in mice
  publication-title: FASEB J
– volume: 11
  start-page: 597
  year: 2001
  end-page: 607
  article-title: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
  publication-title: Pharmacogenetics
– volume: 64
  start-page: 1579
  year: 2002
  end-page: 89
  article-title: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha‐hydroxylase activity in human liver microsomes
  publication-title: Biochem Pharmacol
– volume: 330
  start-page: 87
  year: 1996
  end-page: 96
  article-title: Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway
  publication-title: Arch Biochem Biophys
– volume: 275
  start-page: 4118
  year: 2000
  end-page: 26
  article-title: Formation of 20‐hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11
  publication-title: J Biol Chem
– volume: 41
  start-page: 175
  year: 2005
  end-page: 93
  article-title: Role of 20‐hydroxyeicosatetraenoic acid (20‐HETE) in vascular system
  publication-title: J Smooth Muscle Res
– volume: 334
  start-page: 784
  year: 2010
  end-page: 94
  article-title: Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide
  publication-title: J Pharmacol Exp Ther
– volume: 207
  start-page: 476
  year: 2009
  end-page: 9
  article-title: CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease–the ENCORE Trials
  publication-title: Atherosclerosis
– volume: 33
  start-page: 1677
  year: 2002
  end-page: 84
  article-title: Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack
  publication-title: Stroke
– volume: 19
  start-page: 60
  year: 2013
  end-page: 5
  article-title: A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease
  publication-title: Clin Appl Thromb Hemost
– volume: 332
  start-page: 57
  year: 2010
  end-page: 65
  article-title: 20‐hydroxy‐5,8,11,14‐eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase‐dependent endothelial nitric‐oxide synthase uncoupling
  publication-title: J Pharmacol Exp Ther
– volume: 91
  start-page: 7002
  year: 1994
  end-page: 6
  article-title: Cytochrome P‐450 mediates tissue‐damaging hydroxyl radical formation during reoxygenation of the kidney
  publication-title: Proc Natl Acad Sci USA
– volume: 18
  start-page: 943
  year: 2008
  end-page: 53
  article-title: Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor‐induced chronic kidney disease
  publication-title: Pharmacogenet Genomics
– volume: 25
  start-page: 471
  year: 2012
  end-page: 80
  article-title: Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation
  publication-title: Transpl Int
– volume: 195
  start-page: 199
  year: 2007
  end-page: 206
  article-title: Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction
  publication-title: Atherosclerosis
– volume: 289
  start-page: F496
  year: 2005
  end-page: 503
  article-title: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases
  publication-title: Am J Physiol Renal Physiol
– volume: 30
  start-page: 74
  year: 2007
  end-page: 81
  article-title: Functional polymorphism in human CYP4F2 decreases 20‐HETE production
  publication-title: Physiol Genomics
– volume: 272
  start-page: 12551
  year: 1997
  end-page: 9
  article-title: Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes
  publication-title: J Biol Chem
– volume: 285
  start-page: 1276
  year: 1999
  end-page: 9
  article-title: Anti‐inflammatory properties of cytochrome P450 epoxygenase‐derived eicosanoids
  publication-title: Science
– volume: 89
  start-page: 43
  year: 2009
  end-page: 51
  article-title: 8,9‐Epoxyeicosatrienoic acid protects the glomerular filtration barrier
  publication-title: Prostaglandins Other Lipid Mediat
– volume: 111
  start-page: 63
  year: 2005
  end-page: 9
  article-title: Functional variant of CYP4A11 20‐hydroxyeicosatetraenoic acid synthase is associated with essential hypertension
  publication-title: Circulation
– volume: 53
  start-page: 427
  year: 2013
  end-page: 34
  article-title: CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors
  publication-title: J Clin Pharmacol
– volume: 95
  start-page: 506
  year: 2004
  end-page: 14
  article-title: Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP‐sensitive K+ channels and p42/p44 MAPK pathway
  publication-title: Circ Res
– volume: 76
  start-page: 1623
  year: 2003
  end-page: 30
  article-title: Effect of 11,12‐epoxyeicosatrienoic acid as an additive to St. Thomas’ cardioplegia and University of Wisconsin solutions on endothelium‐derived hyperpolarizing factor‐mediated function in coronary microarteries: influence of temperature and time
  publication-title: Ann Thorac Surg
– volume: 4
  start-page: 39
  year: 1994
  end-page: 42
  article-title: Impaired (S)‐warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
  publication-title: Pharmacogenetics
– volume: 322
  start-page: 76
  year: 1995
  end-page: 86
  article-title: Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform
  publication-title: Arch Biochem Biophys
– volume: 25
  start-page: 703
  year: 2011
  end-page: 13
  article-title: Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice
  publication-title: FASEB J
– volume: 24
  start-page: 1965
  year: 2006
  end-page: 70
  article-title: Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction
  publication-title: J Hypertens
– volume: 6
  start-page: 341
  year: 1996
  end-page: 9
  article-title: The role of the CYP2C9‐Leu359 allelic variant in the tolbutamide polymorphism
  publication-title: Pharmacogenetics
– volume: 40
  start-page: 1353
  year: 2008
  end-page: 6
  article-title: Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation
  publication-title: Transplant Proc
– volume: 22
  start-page: 546
  year: 2009
  end-page: 53
  article-title: Is it possible to predict the early post‐transplant allograft function using 20‐HETE measurements? A preliminary report
  publication-title: Transpl Int
– volume: 24
  start-page: 256
  year: 2014
  end-page: 62
  article-title: Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients
  publication-title: Pharmacogenet Genomics
– volume: 276
  start-page: 36059
  year: 2001
  end-page: 62
  article-title: Epoxygenase pathways of arachidonic acid metabolism
  publication-title: J Biol Chem
– volume: 98
  start-page: 75
  year: 2012
  end-page: 85
  article-title: Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex‐specific relation?
  publication-title: Prostaglandins Other Lipid Mediat
– volume: 46
  start-page: 766
  year: 2005
  end-page: 71
  article-title: Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy
  publication-title: Hypertension
– volume: 327
  start-page: 1052
  year: 2005
  end-page: 7
  article-title: Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes
  publication-title: Biochem Biophys Res Commun
– volume: 61
  start-page: 840
  year: 2002
  end-page: 52
  article-title: Cloning of CYP2J2 gene and identification of functional polymorphisms
  publication-title: Mol Pharmacol
– volume: 69
  start-page: 385
  year: 2013
  end-page: 93
  article-title: ABCB1 polymorphisms are associated with cyclosporine‐induced nephrotoxicity and gingival hyperplasia in renal transplant recipients
  publication-title: Eur J Clin Pharmacol
– volume: 110
  start-page: 2132
  year: 2004
  end-page: 6
  article-title: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2
  publication-title: Circulation
– volume: 26
  start-page: 600
  year: 2004
  end-page: 8
  article-title: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5
  publication-title: Ther Drug Monit
– ident: e_1_2_9_14_1
  doi: 10.1097/00008571-199402000-00005
– ident: e_1_2_9_18_1
  doi: 10.1016/j.prostaglandins.2009.04.004
– ident: e_1_2_9_37_1
  doi: 10.1161/01.HYP.0000182658.04299.15
– ident: e_1_2_9_3_1
  doi: 10.1126/science.285.5431.1276
– ident: e_1_2_9_30_1
  doi: 10.1161/01.RES.0000139436.89654.c8
– ident: e_1_2_9_40_1
  doi: 10.1097/00007691-200412000-00004
– ident: e_1_2_9_25_1
  doi: 10.1016/j.prostaglandins.2011.11.007
– ident: e_1_2_9_19_1
  doi: 10.1073/pnas.91.15.7002
– ident: e_1_2_9_24_1
  doi: 10.1016/j.bbrc.2004.12.116
– ident: e_1_2_9_10_1
  doi: 10.1097/00008571-200110000-00006
– ident: e_1_2_9_27_1
  doi: 10.1016/j.atherosclerosis.2006.11.001
– ident: e_1_2_9_8_1
  doi: 10.1006/abbi.1996.0229
– ident: e_1_2_9_26_1
  doi: 10.1177/1076029611436197
– ident: e_1_2_9_5_1
  doi: 10.1161/01.STR.0000016332.37292.59
– ident: e_1_2_9_12_1
  doi: 10.1016/S0006-2952(02)01354-0
– ident: e_1_2_9_20_1
  doi: 10.1111/j.1432-2277.2008.00829.x
– ident: e_1_2_9_21_1
  doi: 10.1007/s00228-012-1355-x
– ident: e_1_2_9_33_1
  doi: 10.1006/abbi.1995.1438
– ident: e_1_2_9_6_1
  doi: 10.1074/jbc.272.19.12551
– ident: e_1_2_9_31_1
  doi: 10.1016/S0003-4975(03)00735-5
– ident: e_1_2_9_38_1
  doi: 10.1097/01.hjh.0000244944.34546.8e
– volume: 24
  start-page: 256
  year: 2014
  ident: e_1_2_9_41_1
  article-title: Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000045
– ident: e_1_2_9_29_1
  doi: 10.1124/jpet.110.167510
– ident: e_1_2_9_15_1
  doi: 10.1152/physiolgenomics.00003.2007
– ident: e_1_2_9_32_1
  doi: 10.1096/fj.10-171488
– ident: e_1_2_9_35_1
  doi: 10.1124/jpet.109.159863
– ident: e_1_2_9_2_1
  doi: 10.1152/ajprenal.00350.2004
– ident: e_1_2_9_13_1
  doi: 10.1097/00008571-199608000-00007
– ident: e_1_2_9_28_1
  doi: 10.1161/01.CIR.0000143832.91812.60
– ident: e_1_2_9_17_1
  doi: 10.1096/fj.10-160119
– ident: e_1_2_9_16_1
  doi: 10.1161/01.CIR.0000151309.82473.59
– ident: e_1_2_9_11_1
  doi: 10.1124/mol.61.4.840
– ident: e_1_2_9_23_1
  doi: 10.1111/j.1432-2277.2012.01446.x
– ident: e_1_2_9_9_1
  doi: 10.1074/jbc.275.6.4118
– ident: e_1_2_9_36_1
  doi: 10.1016/j.atherosclerosis.2009.06.009
– ident: e_1_2_9_22_1
  doi: 10.1002/jcph.15
– ident: e_1_2_9_34_1
  doi: 10.1097/FPC.0b013e32830e1e16
– ident: e_1_2_9_39_1
  doi: 10.1016/j.transproceed.2008.03.137
– ident: e_1_2_9_4_1
  doi: 10.1540/jsmr.41.175
– ident: e_1_2_9_7_1
  doi: 10.1074/jbc.R100030200
SSID ssj0008132
Score 2.1988113
Snippet Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known...
Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a...
BACKGROUNDArachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1060
SubjectTerms Adult
Allografts - physiology
Arachidonic Acid - genetics
Arachidonic Acid - metabolism
Creatinine clearance
CYP450
Cytochrome P-450 Enzyme System - genetics
Cytochrome P-450 Enzyme System - metabolism
delayed graft function
Female
Genotype
Graft Survival
Homozygote
Humans
Kidney Diseases - genetics
Kidney Diseases - metabolism
Kidney Diseases - surgery
Kidney Transplantation
Male
Middle Aged
Polymorphism, Genetic - genetics
polymorphisms
renal transplant
Retrospective Studies
Title Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation
URI https://api.istex.fr/ark:/67375/WNG-QG2MJ9BM-D/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Feci.12507
https://www.ncbi.nlm.nih.gov/pubmed/26214067
https://www.proquest.com/docview/1716251828
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFD6UFsQXtfXSVVtGEelLls1kchl86m67rYUtVSxWEIa5BUO3iewFtE_9Cf5Gf0nPTC5aqSBCICGcZCYzc3K-M3PONwCv0ETpOA1tEOY5OiixooEyXAYmYiaUCm2cnxqYHCeHp-zoLD5bgTdtLkzND9FNuDnN8P9rp-BSzX9TcquLPlpnn0nuYrUcIHr_izoqC6OaKTxkAeUpbViFXBRP9-QNW7TmmvXbbUDzJm71hmd8Hz63Va7jTc77y4Xq68s_2Bz_85sewL0GkJLdegStw4otN-DOpFlyfwj6pJp-v6iwO4r5xZwUJRl9Ovl59cOnnCBcJY7w-UthHMUukbowZFYtEb8S6SNFCAJMgjewJnjOycy60haeUn0q67yn8hGcjvc_jA6DZmeGQLMoSgOtEVVxnbE8jI1NEFUYbnNp2EDjkfFEpehGuTVQQ_UgTQ3LXBhrZqliXEc2egyrZVXaTSBUqUQluaWpZvhuR0AfxhlPOU10lslBD3baPhK6oS13u2dMReu-YKMJ32g9eNmJfq25Om4Teu07upOQs3MX3JbG4uPxgXh3QCdHfDgRez140Y4EgSrn1lFkaavlXDiGIYSF6Kv24Ek9RLq30YSiy5pgMTu-o_9eEbE_eusvnv676DO4i4AtroMJn8PqYra0WwiKFmob1naHe8PxtteCawQ8B7k
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5VrQS8cB_LaRBCfclq4ziHJV5gabstzaqgVpQHZPmKiLpN0B4S8MRP4DfySxg7BxQVCSFFShRNYsf2ZL6xZz4DPEUTpeM0tEFYFOigxIoGynAZmIiZUCq0cX5qIJ8mkyO2dxwfr8HzLhem4YfoJ9ycZvj_tVNwNyH9m5ZbXQ7RPLtU8g23o7d3qN7-Io_KwqjhCg9ZQHlKW14hF8fTP3rGGm24hv18HtQ8i1y96dm-Ah-6SjcRJyfD1VIN9dc_-Bz_96uuwuUWk5IXzSC6Bmu2ug4X8nbV_Qbog3r25bTGHikXpwtSVmT8_uDHt-8-6wQRK3Gczx9L41h2idSlIfN6hRCWSB8sQhBjEryBVcFzQebWlbb0rOoz2aQ-VTfhaHvrcDwJ2s0ZAs2iKA20RmDFdcaKMDY2QWBhuC2kYSONR8YTlaIn5ZZBDdWjNDUsc5GsmaWKcR3Z6BasV3Vl7wChSiUqKSxNNcN3Ow76MM54ymmis0yOBrDZdZLQLXO520BjJjoPBhtN-EYbwJNe9FND13Ge0DPf072EnJ-4-LY0Fu-mO-LNDs33-MtcvBrA424oCNQ6t5QiK1uvFsKRDCEyRHd1ALebMdK_jSYUvdYEi9n0Pf33ioit8a6_uPvvoo_g4uQw3xf7u9PX9-AS4re4iS28D-vL-co-QIy0VA-9KvwEJbsKYg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7LLiy-eL-M1ygi-9JhmqZpgk86s7MXnWEUF1cQQm7FsrPtMhdQn_wJ_kZ_iSfpRVdWEKHQUk6bNDmn5zvJyReEnoKLMmkWuyjOcwhQUk0ibYWKbEJtrDT4uDA0MJmy_SN6eJweb6Dn7VqYmh-iG3DzlhH-197Az2z-m5E7U_TBO_uV5FuUDbhX6dHbX9xRPE5qqvCYRkRkpKEV8mk83aPnnNGWb9fPFyHN88A1eJ7xFfSxrXOdcHLSX69033z9g87xPz_qKrrcIFL8olaha2jDldfR9qSZc7-BzKyafzmtoD-K5ekSFyUefpj9-PY9rDkBvIo94_OnwnqOXaxMYfGiWgOAxSqkimBAmBhuQE3gnOOF86WtAqf6XNULn8qb6Gi8-264HzVbM0SGJkkWGQOwShhO8zi1jgGssMLlytKBgYMLpjOIo_wkqCVmkGWWcp_Hyh3RVJjEJbfQZlmV7g7CRGumWe5IZii82zPQxykXmSDMcK4GPbTT9pE0DW-53z5jLtv4BRpNhkbroSed6FlN1nGR0LPQ0Z2EWpz47LYsle-ne_LNHpkcipcTOeqhx60mSLA5P5GiSletl9JTDAEuhGC1h27XKtK9jTACMSuDYnZCR_-9InJ3eBAu7v676CO0PRuN5euD6at76BKAt7ROLLyPNleLtXsAAGmlHwZD-AkcUgka
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymorphisms+in+CYP%E2%80%90mediated+arachidonic+acid+routes+affect+the+outcome+of+renal+transplantation&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Gervasini%2C+Guillermo&rft.au=Garc%C3%ADa%E2%80%90Cerrada%2C+Montserrat&rft.au=Vergara%2C+Esther&rft.au=Garc%C3%ADa%E2%80%90Pino%2C+Guadalupe&rft.date=2015-10-01&rft.issn=0014-2972&rft.eissn=1365-2362&rft.volume=45&rft.issue=10&rft.spage=1060&rft.epage=1068&rft_id=info:doi/10.1111%2Feci.12507&rft.externalDBID=10.1111%252Feci.12507&rft.externalDocID=ECI12507
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon